Wells Fargo & Co. lowered shares of Parexel International Corp. (NASDAQ:PRXL) from an outperform rating to a market perform rating in a research report report published on Wednesday.

Other equities analysts also recently issued reports about the stock. Evercore ISI restated a buy rating and set a $78.50 target price (up from $71.00) on shares of Parexel International Corp. in a report on Friday, August 5th. Jefferies Group upped their price objective on shares of Parexel International Corp. from $70.00 to $72.50 and gave the company a hold rating in a report on Friday, August 5th. Deutsche Bank AG upped their price objective on shares of Parexel International Corp. from $65.00 to $71.00 and gave the company a hold rating in a report on Friday, August 5th. Citigroup Inc. upped their price objective on shares of Parexel International Corp. from $74.00 to $80.00 and gave the company a buy rating in a report on Friday, August 5th. Finally, Credit Suisse Group AG reiterated a buy rating on shares of Parexel International Corp. in a report on Tuesday, September 27th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The company currently has an average rating of Hold and an average target price of $66.70.

Analyst Recommendations for Parexel International Corp. (NASDAQ:PRXL)

Shares of Parexel International Corp. (NASDAQ:PRXL) remained flat at $58.16 during midday trading on Wednesday. The stock had a trading volume of 1,083,520 shares. Parexel International Corp. has a 12 month low of $51.16 and a 12 month high of $71.13. The firm has a market cap of $3.10 billion, a P/E ratio of 18.64 and a beta of 0.91. The stock’s 50 day moving average is $62.05 and its 200-day moving average is $64.14.

Parexel International Corp. (NASDAQ:PRXL) last issued its earnings results on Wednesday, October 26th. The company reported $0.76 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.86 by $0.10. The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $525.15 million. Parexel International Corp. had a return on equity of 30.71% and a net margin of 7.09%. Parexel International Corp.’s quarterly revenue was down 2.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 earnings per share. On average, equities research analysts anticipate that Parexel International Corp. will post $3.75 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in Parexel International Corp. by 7.2% in the first quarter. Geode Capital Management LLC now owns 404,974 shares of the company’s stock valued at $25,404,000 after buying an additional 27,205 shares in the last quarter. A.R.T. Advisors LLC purchased a new stake in Parexel International Corp. during the first quarter valued at $884,000. Metropolitan Life Insurance Co. NY boosted its stake in Parexel International Corp. by 4.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 86,769 shares of the company’s stock valued at $5,443,000 after buying an additional 3,389 shares in the last quarter. Magnetar Financial LLC purchased a new stake in Parexel International Corp. during the first quarter valued at $215,000. Finally, Squarepoint Ops LLC purchased a new stake in Parexel International Corp. during the first quarter valued at $875,000. 96.13% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Parexel International Corp. (PRXL) Downgraded by Wells Fargo & Co. to Market Perform” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/24/parexel-international-corp-prxl-downgraded-by-wells-fargo-co-to-market-perform.html.

About Parexel International Corp.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Receive News & Stock Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related stocks with our FREE daily email newsletter.